Further, clinical studies demonstrate that reduced levels of TGFBR3 is associated with an advanced stage in tumour cancer, a poor overall survival phenotype, and, in particular, with hormone receptor-negative and triple-negative tumours. This evidence concerns the gene TGFBR3 and neoplasm.